

# The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, by Roots Analysis

*The light activated therapies market is anticipated to grow at an annualized rate of 27.7% till 2030, by Roots Analysis*

LONDON, ENGLAND, UNITED KINGDOM, October 21, 2021

/EINPresswire.com/ -- Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products

London

[Roots Analysis](#) has announced the addition of "[Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal, 2021-2030](#)" report to its list of offerings.

Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated [therapies market](#) is likely to witness significant growth in the foreseen future.

To order this 140+ page report, which features 80+ figures and 120+ tables, please visit

**Example Highlights**

Light Activated Therapies: Development Pipeline  
*Distribution by Type of Developer'*

Light Activated Therapies: Development Pipeline  
*Distribution by Type of Therapy'*

Light Activated Therapies: Development Pipeline  
*Distribution by Target Patient Segment'*

All charts are accompanied by our observations and professional opinions on the market and anticipated trends

2021 © Roots Analysis

### Light Activated Therapies Market

**Example Highlights**

S. No.	Therapy	Developer(s)	Type of Developer	Type of Light Activated Therapy	Status of Development	Target Indication(s)	Therapeutic Area	Exposure Time	Dose of Light	Light Intensity	Target Patient Segment	Type of Therapy	Dose Frequency
1	Photodynamic Therapy and Meliwa (Bleble)	GALDERMA	Industry	Photodynamic Therapy	Approved	Actinic Keratosis	Skin Disorder	7-10 Minutes	37 Joule / cm <sup>2</sup>	200 mW / cm <sup>2</sup>	Adults, Senior Citizens	Monotherapy	Two Treatments
9	Photodynamic Therapy and Ameluz (Aminolevulinic Acid)	Biofortera	Industry	Photodynamic Therapy	Approved	Actinic Keratosis	Skin Disorder	10 Minutes	37 Joule / cm <sup>2</sup>	200 mW / cm <sup>2</sup>	Adults, Senior Citizens	Monotherapy	Multiple Treatments
29	Photodynamic Therapy and Porphyrin Sodium / Photofin	ADVANZ PHARMACEUTICALS	Industry	Photodynamic Therapy	Approved	Lung Cancer	Oncological Disorder (Skin Tumor)	8-2 Minutes	200 Joule / cm <sup>2</sup>	200 to 275 mW / cm <sup>2</sup>	Adults, Senior Citizens	Monotherapy	Single Treatment / Two Treatments
45	Photodynamic Therapy and Alcare (5-Aminolevulinic Acid)	ALCARE	Industry	Photodynamic Therapy	Approved								
52	Photodynamic Therapy	中国医药集团	Non-Industry	Photodynamic Therapy	Phase II								
62	Hexaminolevulinate Photodynamic Therapy	Shanghai Institute of Materia Medica	Industry / Non-Industry	Photodynamic Therapy	Phase II / III								
67	Photodynamic Therapy and Alcare (5-Aminolevulinic Acid)	ALCARE	Industry	Photodynamic Therapy	Phase II								
71	IRI-1995	Regen Medical	Industry	Photoimmunotherapy	Phase I / II								
103	Photodynamic Therapy and Varnodog	THE UNIVERSITY OF ARIZONA, Genentech	Industry / Non-Industry	Photodynamic Therapy	Phase I								
127	Aurilase Therapy	HANOSPECTRA	Industry	Photothermal Therapy	Early Phase I								

**Distribution by Company Size'**

**Distribution by Location of Headquarters**

2021 © Roots Analysis

### Light Activated Therapies Market by Roots Analysis

<https://www.rootsanalysis.com/reports/light-activated-therapies-market.html>

## Key Market Insights

More than 125 marketed / under development light activated therapies form the current pipeline. At present, 13% of such therapies are marketed, while majority (82%) of the aforementioned candidates are still being evaluated in clinical phases. Examples of approved therapies include Ameluz<sup>®</sup>, Foscan<sup>®</sup>, Hemoporfin<sup>®</sup>, Metvix<sup>®</sup>, Photofrin<sup>®</sup> and Sarotalocan<sup>®</sup>.


Over 485 clinical trials are currently evaluating light activated therapies, worldwide. It is worth mentioning that most of the trials were / are being conducted in North America (34%). More than 28% patients enrolled in trials conducted in the aforementioned region were recruited across different sites in the United States. Further, 69% of the trials are being sponsored by non-industry players.

Over 635 patents have been filed / granted for light activated therapies, since 2018. Over 35% of these intellectual property documents were filed / granted in the North America, with maximum number of patents being filed in US. This is followed by Europe (33%), Asia Pacific and rest of the world (30%).

By 2030, the opportunity within the light activated therapies market is likely to be dominated by the North America.

Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of several advanced stage therapy candidates. Further, Europe and North America (primarily the US) are expected to capture over 80% share of the total market (in terms of sales-based revenues), in 2030.

To request a sample copy / brochure of this report, please visit



## Key Questions Answered

- What are the prevalent R&D trends related to light activated therapies?
- What are the key therapeutic areas for which light activated therapies have been / are being developed?
- What are the key challenges faced by stakeholders engaged in the manufacturing of light activated therapies?
- Who are the leading industry and non-industry players engaged in the development of light activated therapies?
- Across which geographies, extensive research related to light activated therapies is being conducted?
- Which factors are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the light activated therapies market has been analyzed across the following segments:

- Target Indication
  - Head and Neck Cancer
  - Actinic Keratosis
  - Macular Degeneration,
  - Polypoidal Choroidal Vasculopathy
  - Cervical Intraepithelial Neoplasia
  - Bladder Cancer
  - Barrett's Esophagus
  - Gastric Cancer
  - Lung Cancer
  - Port-Wine Stain
  - Others

## □ Key Players

- Key Geographical Regions
  - North America
  - Europe
  - Asia Pacific

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio and recent developments, as well as an informed future outlook.

- ADVANZ PHARMA

□ Biofrontera  
□ Biolitec Pharma  
□ Ozitin  
□ Nanospectra Biosciences  
□ Photoatomic  
□ Rakuten Medical  
□ Steba biotech  
□ Theralase

For additional details, please visit

<https://www.rootsanalysis.com/reports/light-activated-therapies-market.html>

You may also be interested in the following titles:

1. Ec Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030

Contact Details:

Ben Johnson

+1 (415) 800 3415

[ben.johnson@rootsanalysis.com](mailto:ben.johnson@rootsanalysis.com)

Gaurav Chaudhary

Roots Analysis

+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/554386264>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.